Articles tagged with Drug Resistance
Lopatkin's lab will investigate how bacterial metabolism contributes to antibiotic resistance using sophisticated tools and techniques. The research aims to identify drug-resistance mutations that arise in bacteria adapting to different antibiotics and metabolism-altering chemicals.
An interdisciplinary team at MUSC Hollings Cancer Center discovered how P. gingivalis interferes with mitophagy, allowing oral cancer tumors to become resistant to chemotherapy. The study identified the role of fimbriae in attaching to specific proteins on the mitophagic membrane, blocking the chemotherapy drug from its attachment point.
Researchers have uncovered key tumor-stroma interactions that drive drug resistance in melanoma leptomeningeal disease. The study identifies a potential therapeutic target by inhibiting SERPINA3-mediated signaling.
A new study combines bisphosphonates, commonly used for osteoporosis, with azole antifungals to treat fungal infections. The combination effectively targets dermatophytes and prevents resistance development.
Researchers discovered a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. The study found that targeting the degradation of both HER2 and EGFR receptors can overcome drug resistance in HER2-positive breast cancer models.
The study highlights the importance of protease-activated receptors (PARs) in cancer growth and development, with PH-binding motifs identified as a key platform for drug design. The researchers suggest that targeting PARs could provide an alternative to current oncogenic pathways.
A study by Charité researchers found that yeast cells can compensate for aneuploidy by exchanging proteins faster. This mechanism could be used to tackle treatment-resistant tumors and fungal infections. The study identified a previously unknown compensation system based on Saccharomyces cerevisiae.
Researchers found that blocking PI3K-beta makes glioblastoma cells more sensitive to temozolomide treatment, slowing down tumor growth. The study's findings could lead to new treatments for patients with chemotherapy-resistant glioblastoma.
Research found high levels of resistance to critically important antibiotics in uncooked meat, including chicken, lamb, beef, and pork. Uncooked dog food samples also showed similar resistance patterns.
Scientists at German Cancer Research Center have discovered a combination therapy that improves treatment response and delays resistance in lung cancer cells. The therapy, which combines ALK and SRC inhibitors, blocks key protein expression changes that lead to resistance.
A study reveals that melanomas can 'break' parts of their BRAF gene through genomic deletions, creating alternative versions that resist targeted therapy. This discovery opens new avenues for developing effective treatments for patients with BRAF mutations.
Researchers at the University of Eastern Finland have identified coregulator proteins as an alternative target to prevent drug resistance in prostate cancer. By inhibiting these proteins, the growth of drug-resistant cancer cells can be inhibited, and the activity of the glucocorticoid receptor can be limited.
A study published in Psychiatry Research confirms that weight training improves symptoms of anxiety and depression in old people. The analysis of over 200 articles identified the types of training most indicated for these cases, recommending exercises done three times a week with short sets and proper structure.
Researchers developed a breakthrough test to assess the enzymatic activity of glutathione peroxidase 4 (GPX4), a pivotal regulator of ferroptosis. The assay accurately measures GPX4 activity and extends its utility beyond GPX4, allowing for precise evaluation of other enzymes involved in ferroptosis regulation.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
Researchers from the University of Southern Denmark have identified specific groups of cells driving resistance to chemotherapy in TNBC, offering new biomarkers and alternative treatment options. The studies shed light on the mechanisms behind chemoresistance and its epigenetic control.
A study reveals how mechanical constraints in glioblastoma tumors influence the emergence and spatial patterning of cancer stem cells. Piezo1 plays a crucial role in regulating mechanosensing and cell phenotypic switch.
Scientists have extracted a powerful antibacterial peptide from African catfish skin mucus, which could help combat antibiotic-resistant bacteria. The peptide, called NACAP-II, has been shown to disrupt bacterial cell membranes at very low concentrations.
Researchers have developed an AI model called SyntheMol that can design new antibiotics against deadly bacteria like Acinetobacter baumannii. The model identified six potent antibacterial compounds with non-toxic properties, offering a potential solution to the global crisis of antibiotic resistance.
Researchers have identified a crucial interface in a mutated protein that drives lung cancer growth, which could act as a target for more effective treatments. The study used advanced laser imaging techniques to provide unprecedented details of the protein's structure and interactions.
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
Researchers at Weill Cornell Medicine found that patients with drug-resistant tuberculosis (TB) respond similarly to those with drug-sensitive TB when treated with bedaquiline-based second-line medications. The study suggests that treatment duration for drug-resistant TB may be shortened, potentially reducing mortality rates.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
Researchers have developed a new class of antibiotics that can overcome drug-resistant bacteria by targeting the physical and functional integrity of the bacterial cell wall. This could be a game-changer in treating infections, particularly those caused by resistant strains.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
A new study shows that inhibiting TACC3 can restore the effectiveness of T-DM1 in HER2-positive breast cancer cells, which have developed resistance. This is achieved by inducing immunogenic cell death and enhancing the response to the drug.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
Xylazine, a veterinary medication, has been found in the illicit opioid supply, rendering naloxone ineffective in treating overdose cases. Specialized addictions care remains crucial in addressing underlying substance use disorders.
The University of Texas at Arlington is advancing its understanding of deadly disease tuberculosis (TB) with a new research project led by associate professor Kayunta Johnson-Winters. The project aims to understand why certain types of Mycobacterium tuberculosis bacteria do not respond to treatments.
A new proteogenomics study provides insights into how drug resistance develops in acute myeloid leukemia, offering a potential path forward for treatment. Researchers identified specific proteins and molecular locations that play a key role in determining protein activity, which could help doctors switch to alternative medications.
Researchers identified a next-generation BTK degrader that can destroy cellular targets and shrink tumors in drug-resistant CLL patients. The compound, NX-2127, showed promising results in laboratory studies and a phase 1 clinical trial.
A team of researchers found that diffuse anaplasia (DA) subtype of Wilms tumor grows despite high DNA damage and TP53 mutation, leading to resistance to chemotherapy. The study suggests that DA histology emerges through accumulating DNA damage and CNAs, creating selection pressure for TP53 mutations.
Researchers found that resistant bacteria like Klebsiella pneumoniae and Escherichia coli can remain in the body for up to nine years after initial infection. The study's key findings highlight the need for tailored treatment approaches to combat persistent infections.
A recent study has identified a promising solution to combat resistance to protein degraders, which are a novel approach in drug discovery. The researchers found that the drug RBS-10 selectively removes resistant cells by targeting the enzyme NQO1, which is overexpressed in these cells.
Researchers found that high levels of FSP1 are associated with relapse after cisplatin treatment in head and neck squamous cell carcinoma. Targeting FSP1 can attenuate tumor stemness and downregulate invasion and metastatic rates, suggesting a potential new approach for treating drug-tolerant persister cancer cells.
Researchers at Washington State University have discovered a key protein in prostate cancer cells' resistance to docetaxel. Blocking this protein, CHRM1, with dicyclomine restored the effectiveness of docetaxel and reduced tumor growth.
A new study published in Nature Communications has provided structural insights into a potent antimalarial drug candidate's interaction with the malaria parasite Plasmodium falciparum. The research suggests that the drug, TDI-8304, can selectively target and kill resistant parasites, offering hope for more effective treatments against ...
Researchers identified hundreds of genes subject to recent selection in six Candida species, providing valuable knowledge for developing better treatments. The study also found a potential spread of resistance through mating between susceptible and resistant strains.
Researchers analyzed UK and Norway data on antibiotic-resistant bacteria, finding that antibiotic use amplifies the spread, but genetic makeup and environmental pressures are also crucial factors. The study suggests a more nuanced understanding of antibiotic resistance is needed to inform public health interventions.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
Researchers at University of Chicago Medical Center discovered a correlation between gut microbiome composition and postoperative infections in liver transplant patients. The study found that metabolites in fecal samples could predict infection risk with high accuracy, providing a potential diagnostic tool.
Researchers discovered a novel therapeutic target BAMBI that suppresses immune cells, reducing the effectiveness of radiation therapy and inducing therapy resistance in cancer patients. BAMBI's expression is associated with improved survival rates, suggesting it as a promising approach to overcome radiation therapy resistance.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
The Tokyo University of Science team has created a device that enables the simultaneous evaluation of many cancer cells, allowing for rapid and accurate analysis. The system, called cROT, increases throughput to 2,700 cells per hour, making it more than 100 times faster than traditional methods.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
Researchers have identified macrocyclic compounds as a potential solution for targeting proteins critical to tumorigenesis, blocking nearly 80% of cancer's signature characteristic events. Additionally, these small compact molecules can effectively overcome drug resistance by binding to mutant proteins and inhibiting their activities.
Researchers identified a correlation between the HSD3B1 biomarker and resistance to combined hormone therapy and radiotherapy in men with prostate cancer. The study found that high levels of the enzyme led to increased testosterone production, promoting resistance to treatment.
Researchers at Memorial Sloan Kettering Cancer Center have found that lung cancer cells retain a 'memory' of their healthy cell counterparts, which could be exploited to improve treatment with KRAS inhibitors. Eliminating these AT1-like cells improves treatment response to the drugs.
Community antibiotic consumption in the EU increased by 18.8% between 2021 and 2022, reversing a significant decline seen during the pandemic. The resurgence of infections may have contributed to the rebound, but highlights the need for continued prudent use of antibiotics.
Scientists at Texas Biomedical Research Institute found a promising cancer therapy also effectively reduces TB growth, even for drug-resistant bacteria. The therapy combines MCL-1 and BCL-2 inhibitors with antibiotics to control TB up to 98%.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
The ORBITA-2 trial found that stenting improves symptoms compared to a placebo procedure, providing evidence-based treatment for stable chest pain. The study suggests updating guidelines for stable coronary artery disease and offers patients and medical teams two treatment strategies with similar benefits.
The Asian malaria mosquito Anopheles stephensi is spreading drug and diagnostic resistant malaria in Africa, increasing the risk of malaria infections by 270%. Its unique ecology and resistance to insecticides make it challenging for conventional mosquito control tools.
Researchers have discovered highly effective antibodies against P. aeruginosa that can block its type III secretion system and are effective against highly resistant bacteria. These 'pathoblockers' offer a potential therapeutic approach for treating acute and chronic infections with multi-resistant pathogens.
A study led by the University of Sydney found that many antibiotics for childhood infections have less than 50% effectiveness, leading to thousands of unnecessary deaths globally. The World Health Organization has declared antimicrobial resistance a top public health threat, emphasizing the urgent need for updated guidelines.
Researchers have identified polyalthic acid, a compound in copaiba oil, with potent antibacterial activity against Gram-positive bacteria. The study's findings pave the way for developing alternative medications to combat antimicrobial resistance.
Researchers discovered BMAL1 is significantly upregulated in senescent cells and modulates the senescence program through AP-1. The study highlights a previously unappreciated role of BMAL1 in regulating cellular senescence and circadian clock components.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
A University of Melbourne research team is developing an oral therapeutic to restore the activity of common antibiotics used to treat community-acquired bacterial pneumonia. The project aims to combat antibiotic-resistant bacteria and reduce healthcare costs, with potential applications in low- and middle-income countries.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...